Passage Cuts 75% of Workforce After FDA Trial Design Request

Why It Matters

The shift to a randomized controlled trial dramatically raises development costs and timelines for a small biotech, threatening its runway and prompting a drastic restructuring that could reshape the neuro‑degenerative gene‑therapy landscape.

Key Takeaways

• Passage will lay off ~18 employees, 75% of staff.
• FDA now demands randomized trial, rejecting single‑arm design.
• Severance costs estimated at $3.3 million.
• Cash balance $46.3 million, funding through Q1 2027.
• Exploring merger, asset sale, or licensing strategic alternatives.

Pulse Analysis

The FDA’s insistence on a randomized controlled trial for PBFT02 underscores a broader regulatory trend toward more rigorous evidence standards, even for innovative gene‑therapy approaches. While the agency has signaled flexibility with external controls in certain rare‑disease programs, its decision here reflects lingering caution about single‑arm designs, especially when efficacy signals are modest. Companies like Passage must now balance scientific ambition with the practicalities of trial complexity, patient recruitment, and statistical power, all of which can inflate budgets and extend timelines.

Financially, Passage’s decision to slash 75% of its staff translates to a $3.3 million one‑time cost but also reduces ongoing payroll expenses, preserving its $46.3 million cash reserve. That runway, projected to last until early 2027, gives the firm a narrow window to secure additional capital or a strategic partner. Investors will scrutinize the company’s ability to convert the promising biomarker data into a viable product, as the cost of a full‑scale randomized trial could consume a substantial portion of the remaining cash.

Strategically, Passage is signaling openness to mergers, asset sales, or licensing deals, a common exit pathway for niche biotech firms facing regulatory hurdles. A partnership could provide the financial muscle and operational expertise needed to execute a larger trial, while also delivering the gene‑therapy asset to a larger entity with broader commercialization capabilities. For the neurodegenerative market, this move may accelerate consolidation, concentrating expertise and pipelines in firms better equipped to navigate the evolving FDA landscape.